{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-22-001683","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.386595+00:00","generated_at":"2026-06-24T02:04:43.476526+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artelo Biosciences reports Q2 2022 net loss of $2.4M, announces 1-for-15 reverse stock split to regain Nasdaq compliance","bullets":["Net loss $2.4M ($0.87/share) in Q2 2022 vs $2.3M ($1.45/share) in Q2 2021; operating expenses $2.4M.","Cash and investments $21.3M at June 30, 2022, down from $25.6M at Dec 31, 2021; expected to fund operations through end of 2023.","15-for-1 reverse stock split effective August 10, 2022 to improve marketability and regain Nasdaq compliance; shares reduced from 42.6M to ~2.8M.","CAReS study of ART27.13 progresses to fourth cohort (650 mcg); Phase 2b enrollment expected Q4 2022.","Preclinical data for ART26.12 shows efficacy in chemotherapy-induced neuropathy models."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-22-001683","json":"https://secwatch.observer/filing/0001640334-22-001683.json","markdown":"https://secwatch.observer/filing/0001640334-22-001683.md","text":"https://secwatch.observer/filing/0001640334-22-001683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/0001640334-22-001683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:04:43.476526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}